Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MediCane T3:C3 medical cannabis oil for agitation and behavioral disturbances in dementia
MOH_2022-02-22_010632Phase 2Completed
- Sponsor
- MediCane Health
- Start
- May 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Dementia and Alzheimer's disease (AD) comparing T3:C3 Medical Cannabis Oil with Placebo (2 arms). Started May 2021; status: completed.
02
Drugs
medical cannabis oil
03
Conditions
DementiaAlzheimer's disease (AD)
Beyond the preview
Go deeper on MOH_2022-02-22_010632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-22_010632.